You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

CLINICAL TRIALS PROFILE FOR TINIDAZOLE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Tinidazole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003617 ↗ Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach Unknown status Lymphoma Trials Office Phase 3 1995-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known whether chlorambucil is more effective than observation in treating low-grade lymphoma of the stomach. PURPOSE: Randomized phase III trial to compare the effectiveness of chlorambucil with that of no further therapy following anti-Helicobacter therapy in treating patients with low-grade lymphoma of the stomach.
NCT00132171 ↗ Helicobacter Pylori Eradication With a New Sequential Treatment Completed IRCCS Azienda Ospedaliero-Universitaria di Bologna Phase 3 2001-01-01 Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are disappointing, and studies from several countries confirm this poor performance. The study aimed to assess the eradication rate of a new sequential treatment regimen compared with conventional triple therapy for the eradication of H. pylori infection.
NCT00132171 ↗ Helicobacter Pylori Eradication With a New Sequential Treatment Completed St. Orsola Hospital Phase 3 2001-01-01 Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are disappointing, and studies from several countries confirm this poor performance. The study aimed to assess the eradication rate of a new sequential treatment regimen compared with conventional triple therapy for the eradication of H. pylori infection.
NCT00229216 ↗ Treatment of Bacterial Vaginosis With Oral Tinidazole Completed Mission Pharmacal Phase 3 2005-01-01 The purpose of this study is to confirm the safety and efficacy of oral tinidazole for the treatment of bacterial vaginosis.
NCT00313131 ↗ Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments Completed Canadian International Development Agency Phase 3 2004-01-01 This randomised controlled trial aimed to verify whether directly observed single dose treatment (with tinidazole+fluconazole) would be as effective as the longer standard treatments (metronidazole for 7 days, plus vaginal clotrimazole for 3 days) in the syndromic management of women presenting with vaginal discharge in primary health care centers of Ghana, Togo, Guinea and Mali. It was designed as an effectiveness trial, i.e. it was done under conditions typical of routine work in these health centers
NCT00313131 ↗ Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments Completed Université de Sherbrooke Phase 3 2004-01-01 This randomised controlled trial aimed to verify whether directly observed single dose treatment (with tinidazole+fluconazole) would be as effective as the longer standard treatments (metronidazole for 7 days, plus vaginal clotrimazole for 3 days) in the syndromic management of women presenting with vaginal discharge in primary health care centers of Ghana, Togo, Guinea and Mali. It was designed as an effectiveness trial, i.e. it was done under conditions typical of routine work in these health centers
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tinidazole

Condition Name

Condition Name for Tinidazole
Intervention Trials
Helicobacter Pylori Infection 14
Bacterial Vaginosis 6
Helicobacter Infections 2
H. Pylori Infection 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tinidazole
Intervention Trials
Infections 12
Helicobacter Infections 11
Infection 8
Vaginosis, Bacterial 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tinidazole

Trials by Country

Trials by Country for Tinidazole
Location Trials
United States 10
Taiwan 7
China 6
United Kingdom 2
Syrian Arab Republic 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tinidazole
Location Trials
Texas 2
Alabama 2
North Carolina 2
Pennsylvania 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tinidazole

Clinical Trial Phase

Clinical Trial Phase for Tinidazole
Clinical Trial Phase Trials
Phase 4 20
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tinidazole
Clinical Trial Phase Trials
Completed 24
Unknown status 7
Recruiting 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tinidazole

Sponsor Name

Sponsor Name for Tinidazole
Sponsor Trials
Mackay Memorial Hospital 4
Shandong University 2
IRCCS Azienda Ospedaliero-Universitaria di Bologna 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tinidazole
Sponsor Trials
Other 44
Industry 7
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Tinidazole: Clinical Trials, Market Analysis, and Projections

Introduction to Tinidazole

Tinidazole, marketed under the brand name Tindamax, is a synthetic antiprotozoal and antibacterial agent. It belongs to the nitroimidazole class and is effective against various protozoal and bacterial infections, including trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis[1][4].

Clinical Trials and Efficacy

Trichomoniasis and Giardiasis

Clinical trials have demonstrated the efficacy of tinidazole in treating trichomoniasis and giardiasis. For trichomoniasis, tinidazole is indicated for the treatment of infections caused by Trichomonas vaginalis, with a recommendation for simultaneous treatment of sexual partners to prevent re-infection[1].

In the case of giardiasis, tinidazole has been found to be highly effective. A network meta-analysis comparing various treatments for giardiasis concluded that tinidazole has a higher parasitological cure rate compared to metronidazole and albendazole. This study highlighted tinidazole as the best available treatment for giardiasis in both symptomatic and asymptomatic patients[3].

Adverse Reactions and Safety Profile

Clinical studies involving tinidazole have reported adverse reactions in a significant portion of patients. Among 3669 patients treated with a single 2 g dose of tinidazole, adverse reactions were reported by 11.0% of patients. For multi-day dosing, adverse reactions were reported by 13.8% of 1765 patients. Common adverse reactions include gastrointestinal symptoms, headache, and dizziness[1].

Carcinogenicity Concerns

There is a potential risk for carcinogenicity associated with tinidazole, although it has not been directly studied. Given its structural and biological similarities to metronidazole, which has shown carcinogenic effects in mice and rats, the use of tinidazole should be reserved for the indicated conditions[1].

Market Analysis

Current Market Size and Growth

The tinidazole market has been growing steadily, driven by the increasing prevalence of bacterial and parasitic infections. As of 2022, the tinidazole tablet market was valued at USD 0.5 billion and is projected to reach USD 0.8 billion by 2030, growing at a CAGR of 5.6% from 2024 to 2030[2].

Market Drivers

Several factors are driving the growth of the tinidazole market:

  • Increasing Prevalence of Infections: The rising incidence of bacterial and parasitic infections is a significant driver.
  • Improvements in Healthcare Infrastructure: Growing focus on healthcare infrastructure in emerging economies is contributing to market expansion.
  • Urbanization and Rising Disposable Incomes: These factors are expected to shift the sales ratio toward emerging economies[2][5].

Regional Analysis

The global tinidazole market is segmented regionally, with key regions including North America, Europe, and Asia-Pacific. Asia-Pacific, particularly China, leads the global market due to robust domestic demand, supportive policies, and a strong manufacturing base. North America and Europe are experiencing steady growth driven by government initiatives and increasing consumer awareness[5].

Market Segmentation

The tinidazole market is segmented by types (purity levels such as 98% and 99%) and applications (chemical industry and pharmaceutical industry). This segmentation helps in understanding consumer requirements, preferences, and expectations, as well as in developing go-to-market strategies[5].

Market Projections

Future Scope and Trends

The future of the tinidazole market appears promising, with a forecasted CAGR indicating continued growth. Key trends include:

  • Rising Consumer Demand: Increasing awareness and demand for effective treatments for parasitic and bacterial infections.
  • Technological Innovations: Developing technologies and new product developments are expected to fuel market growth.
  • Sustainability and Legislative Backing: Sustainability trends and legislative support are likely to make the market a priority for investors and industry participants[2][5].

Competitive Environment

The competitive environment of the tinidazole market involves strategic positioning based on product life cycles and innovation curves. Companies are focusing on creating marketing plans, defining target market profiles, and implementing sales and distribution strategies to stay competitive[5].

Key Takeaways

  • Efficacy: Tinidazole is highly effective in treating trichomoniasis and giardiasis, with superior parasitological cure rates compared to other treatments.
  • Market Growth: The tinidazole market is growing at a CAGR of 5.6% from 2024 to 2030, driven by increasing infections and improvements in healthcare infrastructure.
  • Regional Dominance: Asia-Pacific, particularly China, leads the global market due to strong domestic demand and supportive policies.
  • Safety Profile: While effective, tinidazole has a notable adverse reaction profile and potential carcinogenicity concerns.

FAQs

What is tinidazole used for?

Tinidazole is used to treat various protozoal and bacterial infections, including trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis[1][4].

What are the common adverse reactions associated with tinidazole?

Common adverse reactions include gastrointestinal symptoms, headache, and dizziness[1].

Is tinidazole more effective than metronidazole for giardiasis?

Yes, tinidazole has been found to have a higher parasitological cure rate compared to metronidazole for the treatment of giardiasis[3].

What are the market drivers for the tinidazole market?

Key drivers include the increasing prevalence of infections, improvements in healthcare infrastructure, urbanization, and rising disposable incomes[2][5].

What is the projected market size of tinidazole by 2030?

The tinidazole tablet market is projected to reach USD 0.8 billion by 2030, growing at a CAGR of 5.6% from 2024 to 2030[2].

Sources

  1. RxList: Tindamax (Tinidazole): Side Effects, Uses, Dosage...
  2. GitHub: Tinidazole Tablet Market Key Drivers and Forecast 2025-2032
  3. PubMed: Comparative efficacy of drugs for treating giardiasis
  4. DrugBank Online: Tinidazole: Uses, Interactions, Mechanism of Action
  5. NewsChannelNebraska: Tinidazole Market Size and Regional Analysis 2024: Market Share...

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.